The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab

F. Heldmann*, Mark J. Brandt, I.E. van der Horst-Bruinsma, R. Landewe, J. Sieper, G. R. Burmester, F. van den Bosch, K. de Vlam, P. Geusens, H. Gaston, S. Schewe, T. Appelboom, P. Emery, M. Dougados, M. Leirisalo-Repo, M. Breban, Joachim Listing, J. Braun

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab'. Together they form a unique fingerprint.

Keyphrases

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology